These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 37945383

  • 1. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    Günther T, Holzleitner N, Viering O, Beck R, Wienand G, Dierks A, Pfob CH, Bundschuh RA, Kircher M, Lapa C, Wester HJ.
    J Nucl Med; 2024 Jan 02; 65(1):33-39. PubMed ID: 37945383
    [Abstract] [Full Text] [Related]

  • 2. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.
    von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, di Santo G, Virgolini IJ.
    J Nucl Med; 2023 Jun 02; 64(6):859-862. PubMed ID: 36657979
    [Abstract] [Full Text] [Related]

  • 3. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E.
    J Nucl Med; 2019 Jul 02; 60(7):1010-1016. PubMed ID: 30530828
    [Abstract] [Full Text] [Related]

  • 4. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.
    Holzleitner N, Fischer S, Maniyankerikalam I, Beck R, Lapa C, Wester HJ, Günther T.
    EJNMMI Res; 2024 Mar 02; 14(1):23. PubMed ID: 38429609
    [Abstract] [Full Text] [Related]

  • 5. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.
    Holzleitner N, Günther T, Daoud-Gadieh A, Lapa C, Wester HJ.
    EJNMMI Res; 2023 Jul 08; 13(1):65. PubMed ID: 37421545
    [Abstract] [Full Text] [Related]

  • 6. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
    Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M.
    J Nucl Med; 2019 Mar 08; 60(3):393-399. PubMed ID: 30002107
    [Abstract] [Full Text] [Related]

  • 7. Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT.
    Koller L, Joksch M, Schwarzenböck S, Kurth J, Heuschkel M, Holzleitner N, Beck R, von Amsberg G, Wester HJ, Krause BJ, Günther T.
    J Nucl Med; 2023 Oct 08; 64(10):1654-1659. PubMed ID: 37934025
    [Abstract] [Full Text] [Related]

  • 8.
    Chopra A.
    ; 2004 Oct 08. PubMed ID: 22787691
    [Abstract] [Full Text] [Related]

  • 9.
    Chopra A.
    ; 2004 Oct 08. PubMed ID: 22855967
    [Abstract] [Full Text] [Related]

  • 10. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
    Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, Castel H, Gandolfo P, von Guggenberg E.
    Pharmaceuticals (Basel); 2023 Feb 13; 16(2):. PubMed ID: 37052226
    [Abstract] [Full Text] [Related]

  • 11. Development of the First 18F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety.
    Günther T, Holzleitner N, Di Carlo D, Urtz-Urban N, Lapa C, Wester HJ.
    Pharmaceutics; 2023 Mar 03; 15(3):. PubMed ID: 36986687
    [Abstract] [Full Text] [Related]

  • 12. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
    Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, Hudson C, Leyton J, Burnet J, Oyen WJ, Blower PJ, Mather SJ, Boerman OC, Sosabowski JK.
    Mol Pharm; 2014 Nov 03; 11(11):3930-7. PubMed ID: 24992368
    [Abstract] [Full Text] [Related]

  • 13. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan 03; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 14. Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy.
    Holzleitner N, Vilangattil M, Swaidan A, Garcia-Prada CD, Taddio MF, Jeanjean P, Mona CE, Lapa C, Casini A, Günther T, Carlucci G.
    Eur J Nucl Med Mol Imaging; 2024 Oct 11. PubMed ID: 39392495
    [Abstract] [Full Text] [Related]

  • 15. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester HJ.
    Theranostics; 2020 Oct 11; 10(18):8264-8280. PubMed ID: 32724470
    [Abstract] [Full Text] [Related]

  • 16. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
    Breeman WA, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Mäcke HR, Krenning EP.
    Nucl Med Biol; 2008 Nov 11; 35(8):839-49. PubMed ID: 19026945
    [Abstract] [Full Text] [Related]

  • 17. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
    Cho EH, Lim JC, Lee SY, Jung SH.
    J Pharmacol Sci; 2016 Jul 11; 131(3):209-14. PubMed ID: 27430985
    [Abstract] [Full Text] [Related]

  • 18. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
    Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D.
    J Nucl Med; 2020 Apr 11; 61(4):520-526. PubMed ID: 31519804
    [Abstract] [Full Text] [Related]

  • 19. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.
    J Nucl Med; 2014 Dec 11; 55(12):2050-6. PubMed ID: 25413139
    [Abstract] [Full Text] [Related]

  • 20. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
    de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, Srinivasan A, Schmidt M, Krenning EP.
    J Nucl Med; 1999 Dec 11; 40(12):2081-7. PubMed ID: 10616889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.